Iron Metabolism Disorders Drugs Market Overview

An overview of conceptual frameworks, analytical approaches of the iron metabolism disorders drugs market is the main objective of the report, which further consists the market opportunity and insights of the data involved in the making of the respective market. Iron metabolism disorders drugs market is expected to grow with significant rate in the near future.

The global iron metabolism disorders drugs market in 2020 is estimated for more than US$ 1.9 Bn and expected to reach a value of US$ 3.2 Bn by 2028 with a significant CAGR of 7.2%.

Iron Metabolism Disorders Drugs Market Dynamics

The rising prevalence of disorders associated with deficiency and overloading of iron, among individuals across the globe is a major factor driving the growth of the global iron metabolism disorders drugs market. For instance, according to data published by National Heart, Lung, and Blood Institute (NHLBI), an estimated 20% of women of childbearing age have iron-deficiency.

In addition, the growing geriatric population, coupled with rising cases of incidence of chronic diseases are some of the major factors expected to fuel the growth of the global market over the forecast period. For instance, as per the data published in ‘An aging world – 2015’ by the U.S. Census Bureau, the geriatric population of people aged 65 years and above is anticipated to increase from 8.5% of the global population in 2015 to 12% in 2030.

Moreover, the increasing number of cases of haemodilution in pregnancy is expected to boost the target market growth to some extent in the near future. Furthermore, increasing government funding, changing lifestyle, rising per-person health care expenditure are factors expected to drive revenue growth of the global market in the coming years.

The rising development of pipeline drugs combined with the growing awareness of the disease in developing countries is expected to create lucrative growth opportunities for the growth of the global iron metabolism deficiency drugs market in the next 10 years. However, the high cost associated with the research and development of iron metabolism deficiency drugs is the major factor expected to restrain the growth of the target market in the near future.

Iron Metabolism Disorders Drugs Market Segmentation

Iron metabolism disorders drugs market is segmented on the basis of drug type, iron metabolism disorder, and by region.

By Iron Metabolism Disorder:

o    Iron Deficiency

o    Iron Overloaded

By Drug Type:

o    Iron isomaltoside 1000

o    Deferasirox

o    Acetylcysteine

o    Deferiprone

o    Metformin

o    Others (Sitagliptin and Erythropoietin)

By Region:

o    North America

o    Europe

o    Asia Pacific

o    Latin America

o    Middle East

o    Africa

Iron Metabolism Disorders Drugs Market Pipeline Drugs Overview

In the global iron metabolism disorder drugs market, seven drugs are in a pipeline including Iron isomaltoside 1000, Deferasirox, Acetylcysteine, Deferiprone, Metformin, Sitagliptin, and Erythropoietin. Iron isomaltoside 1000 drug and Deferasirox have been investigated for the treatment and basic science of iron metabolism disorder, and these drugs are in the 1st and 2nd phase of investigation respectively. Acetylcysteine drug is primarily used as a mucolytic agent and in the management of acetaminophen poisoning. Deferiprone is an oral iron chelator, which is used as second-line agent in thalassemia syndromes when occurs iron overload from blood transfusions.

Source: Drugbank, 2019

Iron Metabolism Disorders Drugs Market Competitive Landscape

Some of the key participating players in the global iron metabolism disorders drugs market are Novartis AG, Cipla Ltd., Sun Pharma Industries Ltd., Natco Pharma Ltd., Teva Pharmaceutical Industries Limited, Zambon Company S.p.A., ApoPharma Inc., and others.

Regional Segmentation

On the basis of region, the iron metabolism disorders drugs market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa.

MMC Overview on Iron Metabolism Disorders Drugs Market Report

The non-identical approach of Meridian Market Consultants stands with conceptual methods backed up with the data analysis. The novel market understanding approach makes up the standard of the assessment results that give a better opportunity for the customers to put their effort.

A research report on the Iron Metabolism Disorders Drugs market by Meridian Market Consultants is an in-depth and extensive study of the market based on the necessary data crunching and statistical analysis. It provides a brief view of the dynamics flowing through the market, which includes the factors that support the market and the factors that are acting as impedance for the growth of the market.

Furthermore, the report includes the various trends and opportunities in the respective market in different regions for a better understanding of readers that helps to analyze the potential of the market. The report is titled ‘Iron Metabolism Disorders Drugs Market: Opportunity Analysis and Future Assessment 2020-2028’.

Factors that are benchmarked while estimating the market

Various factors that are benchmarked while estimating the market growth include (but not restricted to):

•    New product designs and launches

•    Current product compliance

•    Reimbursement

•    Concerns for use of Iron Metabolism Disorders Drugs

•    Advantages of Iron Metabolism Disorders Drugs

Actions taken by the manufacturer and respective regulatory authorities also impact the market growth of the segment. These factors are understood at a regional level and in major countries globally for providing regional insights into the product segment in the report. This helps our clients to make an informed decision.

A mix of top-down and bottom-up approach is followed to arrive at and validate our market value estimations. For a product segment wherein one/two manufacturer(s) dominates the market, its product sales, previous growth rates, and market expansion plans are considered to generate market share in the global market.

1.    Global Iron Metabolism Disorders Drugs Market Report Overview

1.1.    Introduction

1.2.    Report Description

1.3.    Methodology

2.    Global Iron Metabolism Disorders Drugs Market Overview

2.1.    Introduction

2.1.1.    Market Definition

2.1.2.    Market Taxonomy

2.2.    Executive Summary

2.3.    Global Iron Metabolism Disorders Drugs Market Snapshot

2.4.    Global Iron Metabolism Disorders Drugs Market Size and Forecast, 2020–2028

2.4.1.    Introduction

2.4.2.    Market Value Forecast and Annual Growth Rate (AGR) Comparison (2020–2028)

2.5.    Global Iron Metabolism Disorders Drugs Market Dynamics

2.5.1.    Drivers

2.5.2.    Restraints

2.5.3.    Opportunity

2.5.4.    Trends

2.6.    Key Regulations

2.7.    Porter’s Five Forces Model

3.    Global Iron Metabolism Disorders Drugs Market, By Iron Metabolism Disorders

3.1.    Introduction

3.1.1.    Annual Growth Rate Comparison, By Iron Metabolism Disorders

3.1.2.    BPS Analysis, By Iron Metabolism Disorders

3.2.    Market Revenue (US$Mn) Forecast, By Iron Metabolism Disorders

3.2.1.    Iron Deficiency

3.2.2.    Iron Overloaded

3.3.    Global Iron Metabolism Disorders Drugs Market Attractiveness Index, By Iron Metabolism Disorders

4.    Global Iron Metabolism Disorders Drugs Market, By Drug Type

4.1.    Introduction

4.1.1.    Annual Growth Rate Comparison, By Drug Type

4.1.2.    BPS Analysis, By Drug Type

4.2.    Market Revenue (US$Mn) Forecast, By Drug Type

4.2.1.    Iron isomaltoside 1000

4.2.2.    Deferasirox

4.2.3.    Acetylcysteine

4.2.4.    Deferiprone

4.2.5.    Metformin

4.2.6.    Others (Sitagliptin and Erythropoietin)

4.3.    Global Iron Metabolism Disorders Drugs Market Attractiveness Index, By Drug Type

5.    Global Iron Metabolism Disorders Drugs Market, By Region

5.1.    Introduction

5.1.1.    Annual Growth Rate Comparison, By Region

5.1.2.    BPS Analysis, By Region

5.2.    Market Revenue (US$Mn) Forecast, By Region

5.2.1.    North America

5.2.2.    Latin America

5.2.3.    Europe

5.2.4.    Asia Pacific

5.2.5.    Middle East

5.2.6.    Africa

5.3.    Global Iron Metabolism Disorders Drugs Market Attractiveness Index, By Region

6.    North America Iron Metabolism Disorders Drugs Market Analysis and Forecast, 2020–2028

6.1.    Introduction

6.1.1.    Annual Growth Rate Comparison, By Country

6.1.2.    BPS Analysis, By Country

6.2.    Market Revenue (US$Mn) Forecast, By Country

6.2.1.    U.S. Iron Metabolism Disorders Drugs Market

6.2.2.    Canada Iron Metabolism Disorders Drugs Market

6.3.    North America Iron Metabolism Disorders Drugs Market, By Iron Metabolism Disorders

6.3.1.    Iron Deficiency

6.3.2.    Iron Overloaded

6.4.    North America Iron Metabolism Disorders Drugs Market, By Drug Type

6.4.1.    Iron isomaltoside 1000

6.4.2.    Deferasirox

6.4.3.    Acetylcysteine

6.4.4.    Deferiprone

6.4.5.    Metformin

6.4.6.    Others (Sitagliptin and Erythropoietin)

6.5.    North America Iron Metabolism Disorders Drugs Market Attractiveness Index

6.5.1.    By Country

6.5.2.    By Iron Metabolism Disorders

6.5.3.    By Drug Type

7.    Latin America Iron Metabolism Disorders Drugs Market Analysis and Forecast, 2020–2028

7.1.    Introduction

7.1.1.    Annual Growth Rate Comparison, By Country

7.1.2.    BPS Analysis, By Country

7.2.    Market (US$Mn) Forecast, By Country

7.2.1.    Brazil Iron Metabolism Disorders Drugs Market

7.2.2.    Mexico Iron Metabolism Disorders Drugs Market

7.2.3.    Argentina Iron Metabolism Disorders Drugs Market

7.2.4.    Rest of Latin America Iron Metabolism Disorders Drugs Market

7.3.    Latin America Iron Metabolism Disorders Drugs Market, By Iron Metabolism Disorders

7.3.1.    Iron Deficiency

7.3.2.    Iron Overloaded

7.4.    Latin America Iron Metabolism Disorders Drugs Market, By Drug Type

7.4.1.    Iron isomaltoside 1000

7.4.2.    Deferasirox

7.4.3.    Acetylcysteine

7.4.4.    Deferiprone

7.4.5.    Metformin

7.4.6.    Others (Sitagliptin and Erythropoietin)

7.5.    Latin America Iron Metabolism Disorders Drugs Market Attractiveness Index

7.5.1.    By Country

7.5.2.    By Iron Metabolism Disorders

7.5.3.    By Drug Type

8.    Europe Iron Metabolism Disorders Drugs Market Analysis and Forecast, 2020–2028

8.1.    Introduction

8.1.1.    Annual Growth Rate Comparison, By Country

8.1.2.    BPS Analysis, By Country

8.2.    Market (US$Mn) Forecast, By Country

8.2.1.    U.K. Iron Metabolism Disorders Drugs Market

8.2.2.    Germany Iron Metabolism Disorders Drugs Market

8.2.3.    Italy Iron Metabolism Disorders Drugs Market

8.2.4.    France Iron Metabolism Disorders Drugs Market

8.2.5.    Spain Iron Metabolism Disorders Drugs Market

8.2.6.    Russia Iron Metabolism Disorders Drugs Market

8.2.7.    Poland Iron Metabolism Disorders Drugs Market

8.2.8.    BENELUX Iron Metabolism Disorders Drugs Market

8.2.9.    NORDIC Iron Metabolism Disorders Drugs Market

8.2.10.    Rest of Europe Iron Metabolism Disorders Drugs Market

8.3.    Europe Iron Metabolism Disorders Drugs Market, By Iron Metabolism Disorders

8.3.1.    Iron Deficiency

8.3.2.    Iron Overloaded

8.4.    Europe Iron Metabolism Disorders Drugs Market, By Drug Type

8.4.1.    Iron isomaltoside 1000

8.4.2.    Deferasirox

8.4.3.    Acetylcysteine

8.4.4.    Deferiprone

8.4.5.    Metformin

8.4.6.    Others (Sitagliptin and Erythropoietin)

8.5.    Europe Iron Metabolism Disorders Drugs Market Attractiveness Index

8.5.1.    By Country

8.5.2.    By Iron Metabolism Disorders

8.5.3.    By Drug Type

9.    Asia Pacific Iron Metabolism Disorders Drugs Market Analysis and Forecast, 2020–2028

9.1.    Introduction

9.1.1.    Annual Growth Rate Comparison, By Country

9.1.2.    BPS Analysis, By Country

9.2.    Market (US$Mn) Forecast, By Country

9.2.1.    China Iron Metabolism Disorders Drugs Market

9.2.2.    India Iron Metabolism Disorders Drugs Market

9.2.3.    Japan Iron Metabolism Disorders Drugs Market

9.2.4.    Australia and New Zealand Iron Metabolism Disorders Drugs Market

9.2.5.    South Korea Iron Metabolism Disorders Drugs Market

9.2.6.    ASEAN Iron Metabolism Disorders Drugs Market

9.2.7.    Rest of Asia Pacific Iron Metabolism Disorders Drugs Market

9.3.    Asia Pacific Iron Metabolism Disorders Drugs Market, By Iron Metabolism Disorders

9.3.1.    Iron Deficiency

9.3.2.    Iron Overloaded

9.4.    Asia Pacific Iron Metabolism Disorders Drugs Market, By Drug Type

9.4.1.    Iron isomaltoside 1000

9.4.2.    Deferasirox

9.4.3.    Acetylcysteine

9.4.4.    Deferiprone

9.4.5.    Metformin

9.4.6.    Others (Sitagliptin and Erythropoietin)

9.5.    Asia Pacific Iron Metabolism Disorders Drugs Market Attractiveness Index

9.5.1.    By Country

9.5.2.    By Iron Metabolism Disorders

9.5.3.    By Drug Type

10.    Middle East Iron Metabolism Disorders Drugs Market, By Region

10.1.    Introduction

10.1.1.    Annual Growth Rate Comparison, By Country

10.1.2.    BPS Analysis, By Country

10.2.    Market (US$Mn) Forecast, By Country

10.2.1.    GCC Countries Iron Metabolism Disorders Drugs Market

10.2.2.    Israel Iron Metabolism Disorders Drugs Market

10.2.3.    Oman Iron Metabolism Disorders Drugs Market

10.2.4.    Rest of Middle East Iron Metabolism Disorders Drugs Market

10.3.    Middle East Iron Metabolism Disorders Drugs Market, By Iron Metabolism Disorders

10.3.1.    Iron Deficiency

10.3.2.    Iron Overloaded

10.4.    Middle East Iron Metabolism Disorders Drugs Market, By Drug Type

10.4.1.    Iron isomaltoside 1000

10.4.2.    Deferasirox

10.4.3.    Acetylcysteine

10.4.4.    Deferiprone

10.4.5.    Metformin

10.4.6.    Others (Sitagliptin and Erythropoietin)

10.5.    Middle East Iron Metabolism Disorders Drugs Market Attractiveness Index

10.5.1.    By Country

10.5.2.    By Iron Metabolism Disorders

10.5.3.    By Drug Type

11.    Africa Iron Metabolism Disorders Drugs Market, By Region

11.1.    Introduction

11.1.1.    Annual Growth Rate Comparison, By Country

11.1.2.    BPS Analysis, By Country

11.2.    Market (US$Mn) Forecast, By Country

11.2.1.    South Africa Iron Metabolism Disorders Drugs Market

11.2.2.    Egypt Iron Metabolism Disorders Drugs Market

11.2.3.    North Africa Iron Metabolism Disorders Drugs Market

11.2.4.    Rest of Africa Iron Metabolism Disorders Drugs Market

11.3.    Africa Iron Metabolism Disorders Drugs Market, By Iron Metabolism Disorders

11.3.1.    Iron Deficiency

11.3.2.    Iron Overloaded

11.4.    Africa Iron Metabolism Disorders Drugs Market, By Drug Type

11.4.1.    Iron isomaltoside 1000

11.4.2.    Deferasirox

11.4.3.    Acetylcysteine

11.4.4.    Deferiprone

11.4.5.    Metformin

11.4.6.    Others (Sitagliptin and Erythropoietin)

11.5.    Africa Iron Metabolism Disorders Drugs Market Attractiveness Index

11.5.1.    By Country

11.5.2.    By Iron Metabolism Disorders

11.5.3.    By Drug Type

12.    Recommendation

12.1.    Market Strategy

13.    Competitive Landscape

13.1.    Competition Dashboard

13.2.    List and Company Overview of Global Key Players

13.3.    Company Profiles

13.3.1.    Novartis AG

13.3.1.1.    Company Overview

13.3.1.2.    Financial Overview

13.3.1.3.    Iron Metabolism Disorders Portfolio

13.3.1.4.    Key Developments

13.3.1.5.    Business Strategies

13.3.2.    Cipla Ltd.

13.3.3.    Sun Pharma Industries Ltd.

13.3.4.    Natco Pharma Ltd.

13.3.5.    Teva Pharmaceutical Industries Limited

13.3.6.    Zambon Company S.p.A.

13.3.7.    ApoPharma Inc.

14.    Acronyms